FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote

FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote
Paratek Pharmaceuticals’ first drug, and the first in a new class of broad-spectrum antibiotics called aminomethylcyclines, has shown to be noninferior to current regimens for bacterial pneumonia and skin infections, FDA reviewers wrote ahead of an Aug. 8 advisory committee meeting.
Source: FierceMedicalDevices News
FDA notes Paratek antibiotic’s noninferiority as it heads to AdComm vote